Page 1 of 1
New article in Blood re Jak inhibitors and lymphoid malignancy
Posted: Sat Aug 18, 2018 6:52 am
by biopearl123
Here's the reference: No mention of Imetelstat in article or references. Mainly describes possible increased risk of lymphoma (B-cell) and JAK inhibition.
http://www.bloodjournal.org/content/132 ... ecked=true
Re: New article in Blood re Jak inhibitors and lymphoid malignancy
Posted: Sat Aug 18, 2018 9:51 pm
by Dogonenuts
BP, this is a pretty strong arguement for an alternative Tx for MF, MDS and would open the door for first line Tx once approved in the r/r setting. The authors’ demanding further investigation of Jak inhibitors being related to a 16 fold increase in likelihood of developing an aggressive lymphoma is an aggressive statement.
Thx for the link.
Nuts
Re: New article in Blood re Jak inhibitors and lymphoid malignancy
Posted: Sat Aug 18, 2018 9:52 pm
by Dogonenuts
BP, this is a pretty strong arguement for an alternative Tx for MF, MDS and would open the door for first line Tx once approved in the r/r setting. The authors’ demanding further investigation of Jak inhibitors being related to a 16 fold increase in likelihood of developing an aggressive lymphoma is an aggressive statement.
Thx for the link.
Nuts
Re: New article in Blood re Jak inhibitors and lymphoid malignancy
Posted: Sun Aug 19, 2018 1:53 am
by biopearl123
Nuts, agreed, you will get no argument from me. JAK inhibitors reduce spleen size but do not appear to prolong life once one gets to the R/R stage, in fact by definition, therapy with JAK inhibitors does not help this group. So as with many therapies, symptom improvement comes with a price, including an increased risk of some malignancies. So far I have not seen much about JAK inhibitors affecting the malignant clone in a selective fashion, not improving MOS the way Imetelstat appears to, and not being associated with remissions. Its not hard to envision Imetelstat finding its way to front line, the problem of "clonal drift" remains but we have only started to see where combination therapy will go. (But first the FDA needs to approve for R/R). bp
Re: New article in Blood re Jak inhibitors and lymphoid malignancy
Posted: Sun Aug 19, 2018 3:10 am
by Dogonenuts
When I see articles like this and then consider the revenues the likes of Incyte and Celgene are bringing in for tx that is of very limited value, I have to believe someone was paid off at the FDA for the clinical hold on imet that almost ruined the company and greatly devalued GERN’s market cap. I wish someone in our circle had the means or connections to look deeply into that. The LFT elevations that were cited were very small considering the range of AE’s seen in the oncology drug world. I sincerely hope JNJ can get a makeup call by the FDA with a couple of AA’s to start with.
Nuts